FY2017 Earnings Estimate for Amicus Therapeutics, Inc. (FOLD) Issued By Leerink Swann

Amicus Therapeutics, Inc. (NASDAQ:FOLD) – Equities researchers at Leerink Swann boosted their FY2017 earnings per share (EPS) estimates for shares of Amicus Therapeutics in a note issued to investors on Tuesday. Leerink Swann analyst J. Schwartz now expects that the biopharmaceutical company will earn ($1.76) per share for the year, up from their prior estimate of ($1.77). Leerink Swann currently has a “Outperform” rating and a $24.00 target price on the stock. Leerink Swann also issued estimates for Amicus Therapeutics’ Q4 2017 earnings at ($0.33) EPS.

FOLD has been the subject of several other reports. Zacks Investment Research lowered shares of Amicus Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, December 19th. Robert W. Baird set a $20.00 price objective on shares of Amicus Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, February 7th. BidaskClub upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, January 15th. Cowen restated a “buy” rating and issued a $22.00 price objective on shares of Amicus Therapeutics in a report on Wednesday, January 10th. Finally, ValuEngine upgraded Amicus Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $19.06.

Amicus Therapeutics (NASDAQ:FOLD) opened at $15.17 on Thursday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 6.22 and a current ratio of 6.32. The company has a market cap of $2,607.10, a price-to-earnings ratio of -8.29 and a beta of 1.46. Amicus Therapeutics has a one year low of $5.87 and a one year high of $17.40.

In other Amicus Therapeutics news, CEO John F. Crowley sold 65,581 shares of the business’s stock in a transaction dated Thursday, December 21st. The shares were sold at an average price of $13.51, for a total value of $885,999.31. Following the completion of the transaction, the chief executive officer now directly owns 393,076 shares in the company, valued at $5,310,456.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jay Barth sold 20,000 shares of the business’s stock in a transaction dated Tuesday, January 23rd. The stock was sold at an average price of $16.80, for a total transaction of $336,000.00. Following the completion of the transaction, the insider now owns 105,409 shares of the company’s stock, valued at $1,770,871.20. The disclosure for this sale can be found here. Insiders sold 250,390 shares of company stock valued at $3,620,581 over the last quarter. 3.40% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently bought and sold shares of FOLD. Teachers Advisors LLC increased its holdings in shares of Amicus Therapeutics by 3.2% during the second quarter. Teachers Advisors LLC now owns 261,545 shares of the biopharmaceutical company’s stock valued at $2,634,000 after acquiring an additional 8,046 shares in the last quarter. TIAA CREF Investment Management LLC increased its holdings in shares of Amicus Therapeutics by 12.0% during the second quarter. TIAA CREF Investment Management LLC now owns 487,751 shares of the biopharmaceutical company’s stock valued at $4,912,000 after acquiring an additional 52,136 shares in the last quarter. Nationwide Fund Advisors increased its holdings in shares of Amicus Therapeutics by 27.9% during the second quarter. Nationwide Fund Advisors now owns 168,709 shares of the biopharmaceutical company’s stock valued at $1,699,000 after acquiring an additional 36,764 shares in the last quarter. Amalgamated Bank increased its holdings in shares of Amicus Therapeutics by 5.7% during the second quarter. Amalgamated Bank now owns 18,451 shares of the biopharmaceutical company’s stock valued at $186,000 after acquiring an additional 1,002 shares in the last quarter. Finally, New York State Common Retirement Fund increased its holdings in shares of Amicus Therapeutics by 8.3% during the second quarter. New York State Common Retirement Fund now owns 153,500 shares of the biopharmaceutical company’s stock valued at $1,546,000 after acquiring an additional 11,699 shares in the last quarter.

ILLEGAL ACTIVITY WARNING: “FY2017 Earnings Estimate for Amicus Therapeutics, Inc. (FOLD) Issued By Leerink Swann” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/02/17/fy2017-earnings-estimate-for-amicus-therapeutics-inc-fold-issued-by-leerink-swann.html.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Earnings History and Estimates for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply